Daily Stock Analysis, ACRX, AcelRx Pharmaceuticals Inc, priceseries

AcelRx Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
2.65
Close
2.60
High
2.65
Low
2.50
Previous Close
2.65
Daily Price Gain
-0.05
YTD High
3.60
YTD High Date
Mar 3, 2017
YTD Low
2.25
YTD Low Date
May 18, 2017
YTD Price Change
0.05
YTD Gain
1.96%
52 Week High
4.08
52 Week High Date
Sep 28, 2016
52 Week Low
2.25
52 Week Low Date
May 18, 2017
52 Week Price Change
-0.71
52 Week Gain
-21.45%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 18. 2014
6.39
Jan 6. 2015
6.71
11 Trading Days
5.04%
Link
LONG
Feb 11. 2015
7.24
Mar 6. 2015
8.58
16 Trading Days
18.45%
Link
LONG
Apr 10. 2015
4.06
Apr 27. 2015
4.35
11 Trading Days
7.20%
Link
LONG
May 29. 2015
3.50
Jun 17. 2015
4.04
13 Trading Days
15.42%
Link
LONG
Oct 30. 2015
3.94
Dec 1. 2015
5.25
21 Trading Days
33.35%
Link
LONG
Jan 25. 2016
3.13
Feb 8. 2016
3.36
10 Trading Days
7.20%
Link
LONG
Jul 5. 2016
2.77
Jul 19. 2016
2.96
10 Trading Days
6.90%
Link
LONG
Jul 26. 2016
3.00
Aug 16. 2016
3.58
15 Trading Days
19.34%
Link
LONG
Sep 14. 2016
3.28
Oct 6. 2016
3.76
16 Trading Days
14.78%
Link
Company Information
Stock Symbol
ACRX
Exchange
NasdaqGM
Company URL
www.acelrx.com
Company Phone
650-216-3500
CEO
Vincent J. Angotti
Headquarters
California
Business Address
351 GALVESTON DRIVE, REDWOOD CITY, CA 94063
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Appliances & Equipment
CIK
0001427925
About

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of therapies for the treatment of actual pain. Its lead product candidate includes ZalvisoTM intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system. It is designed to address the problems associated with post-operative intravenous patient-controlled analgesia, or IV PCA. AcelRx Pharmaceuticals was founded by Thomas A. Schreck and Pamela P. Palmer on July 13, 2005 and is headquartered in Redwood City, CA.

Description

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain. The company's late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. Zalviso is approved in the European Union, Switzerland, Liechtenstein, Iceland, Norway and Australia, or the Territory; and is under development stage in the United States. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.